CONCERTA Methylphenidate — Sales to customers (Note 9)
Products & Services · Sales to customers (Note 9)Johnson & Johnson CONCERTA Methylphenidate — Sales to customers (Note 9) decreased by 14.1% to $281.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 1.4%, from $285.00M to $281.00M. Over 2 years (FY 2021 to FY 2024), CONCERTA Methylphenidate — Sales to customers (Note 9) shows relatively stable performance with a 1.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market adoption or higher prescription volumes, while a decrease may signal increased generic competition or a shift in therapeutic treatment patterns.
Detailed definition
This metric represents the total net revenue generated from the sale of Concerta and related methylphenidate products to...
Peer comparison
Comparable to branded pharmaceutical product revenue lines reported by peers in the CNS or ADHD therapeutic categories.
jnj_segment_concerta_methylphenidate_sales_to_customers_note_9Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $341.00M | $323.00M | $314.00M | $382.00M | $314.00M | $322.00M | $316.00M | $412.00M | $379.00M | $354.00M | $326.00M | $285.00M | $317.00M | $296.00M | $327.00M | $281.00M |
| QoQ Change | — | -5.3% | -2.8% | +21.7% | -17.8% | +2.5% | -1.9% | +30.4% | -8.0% | -6.6% | -7.9% | -12.6% | +11.2% | -6.6% | +10.5% | -14.1% |
| YoY Change | — | — | — | — | -7.9% | -0.3% | +0.6% | +31.2% | +17.7% | — | -20.9% | -24.8% | — | -16.4% | +0.3% | -1.4% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's concerta methylphenidate — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported concerta methylphenidate — sales to customers (note 9) of $281.00M in Q3 2025.
- How has Johnson & Johnson's concerta methylphenidate — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's concerta methylphenidate — sales to customers (note 9) decreased by 1.4% year-over-year, from $285.00M to $281.00M.
- What is the long-term trend for Johnson & Johnson's concerta methylphenidate — sales to customers (note 9)?
- Over 2 years (2021 to 2024), Johnson & Johnson's concerta methylphenidate — sales to customers (note 9) has grown at a 1.5% compound annual growth rate (CAGR), from $1.24B to $1.28B.
- What does concerta methylphenidate — sales to customers (note 9) mean?
- The total revenue earned from selling Concerta and methylphenidate products to customers.